'Last July the first predictive clinical test based on the gut microbiome was approved in Europe. The test, called BiomeOne, was developed by Vienna-based biotech BiomeDx. It analyzes the DNA in gut microbes of patients with cancer and predicts who are most likely to have success with immunotherapy.'

https://www.nature.com/articles/s41587-023-01677-z?utm_source=linkedin&utm_medium=social&utm_content=organic&utm_campaign=CONR_JRNLS_AWA1_GL_SCON_SMEDA_NATUREPORTFOLIO